Johnson & Johnson (JNJ.N)
JNJ.N on New York Stock Exchange
138.64USD
25 Sep 2018
138.64USD
25 Sep 2018
Change (% chg)
$-1.83 (-1.30%)
$-1.83 (-1.30%)
Prev Close
$140.47
$140.47
Open
$140.53
$140.53
Day's High
$140.90
$140.90
Day's Low
$138.40
$138.40
Volume
2,306,458
2,306,458
Avg. Vol
1,941,479
1,941,479
52-wk High
$148.32
$148.32
52-wk Low
$118.62
$118.62
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 2.03 | December | 26 Sep 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 5 | 6 | 6 | 6 |
| (2) OUTPERFORM | 4 | 4 | 4 | 4 |
| (3) HOLD | 9 | 9 | 9 | 7 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 1 |
| (5) SELL | 1 | 1 | 1 | 2 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.37 | 2.30 | 2.30 | 2.45 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 12 | 20,026.80 | 20,465.00 | 19,706.90 | 20,092.40 |
| Quarter Ending Dec-18 | 12 | 20,373.40 | 21,002.50 | 19,802.00 | 20,925.40 |
| Year Ending Dec-18 | 15 | 81,257.40 | 82,151.90 | 80,601.00 | 79,978.80 |
| Year Ending Dec-19 | 16 | 83,185.10 | 85,268.00 | 80,593.00 | 83,407.30 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 16 | 2.03 | 2.09 | 1.97 | 1.92 |
| Quarter Ending Dec-18 | 16 | 1.95 | 2.02 | 1.88 | 1.89 |
| Year Ending Dec-18 | 17 | 8.14 | 8.21 | 8.11 | 7.74 |
| Year Ending Dec-19 | 19 | 8.63 | 8.97 | 8.41 | 8.22 |
| LT Growth Rate (%) | 6 | 7.76 | 9.00 | 4.60 | 6.15 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Jun-18 | 20,390.00 | 20,830.00 | 440.04 | 2.16 |
| Quarter Ending Mar-18 | 19,460.40 | 20,009.00 | 548.56 | 2.82 |
| Quarter Ending Dec-17 | 20,072.50 | 20,195.00 | 122.52 | 0.61 |
| Quarter Ending Sep-17 | 19,282.80 | 19,650.00 | 367.23 | 1.90 |
| Quarter Ending Jun-17 | 18,934.90 | 18,839.00 | 95.86 | 0.51 |
| Earnings (per share) | ||||
| Quarter Ending Jun-18 | 2.07 | 2.10 | 0.03 | 1.44 |
| Quarter Ending Mar-18 | 2.02 | 2.06 | 0.04 | 2.07 |
| Quarter Ending Dec-17 | 1.72 | 1.74 | 0.02 | 0.96 |
| Quarter Ending Sep-17 | 1.80 | 1.90 | 0.10 | 5.46 |
| Quarter Ending Jun-17 | 1.80 | 1.83 | 0.03 | 1.92 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 20,026.80 | 20,026.80 | 19,987.00 | 20,019.20 | 20,092.40 |
| Quarter Ending Dec-18 | 20,373.40 | 20,373.40 | 20,340.10 | 20,404.10 | 20,925.40 |
| Year Ending Dec-18 | 81,257.40 | 81,257.40 | 81,206.10 | 81,273.20 | 79,978.80 |
| Year Ending Dec-19 | 83,185.10 | 83,185.10 | 83,172.60 | 83,480.00 | 83,407.30 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 2.03 | 2.03 | 2.03 | 2.02 | 1.92 |
| Quarter Ending Dec-18 | 1.95 | 1.95 | 1.95 | 1.95 | 1.89 |
| Year Ending Dec-18 | 8.14 | 8.14 | 8.14 | 8.14 | 7.74 |
| Year Ending Dec-19 | 8.63 | 8.63 | 8.59 | 8.59 | 8.22 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 1 | 1 |
| Earnings | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 1 | 1 |
Earnings vs. 
Estimates- California judge declares mistrial in J&J talc cancer case
- Exclusive: India, U.S. closing in on package deal to remove trade irritants
- J&J to work with India on compensation for recalled hip implants
- J&J ducks lawsuit seeking economic damages for talc product buyers
- Bayer, J&J cleared of liability in latest Xarelto trial